Skip to main content
. 2013 Jun 3;4(9):1322–1332. doi: 10.1021/cn400116z

Figure 5.

Figure 5

Evaluation of MJN110 for inhibition of rat and human serine hydrolases. (A) In vitro competitive ABPP profiles of MJN110 in rat brain (membrane) proteomes. (B) Competitive ABPP profiles showing serine hydrolase activities in brain and liver proteomes isolated from rats treated with either vehicle or MJN110 (1–40 mg·kg–1, i.p.) for 4 h. (C) Inhibition of recombinant hMAGL and hFAAH by MJN110 as measured by gel-based competitive ABPP with FP-Rh. (D) MJN110-mediated inhibition of recombinant hMAGL and hFAAH activity as measured by hydrolysis of 2-AG and AEA, respectively. (E) Competitive ABPP profiles of human-derived PC3 cells following in situ treatment with MJN110 for 4 h.